Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $41.00 by Analysts at Scotiabank

Keros Therapeutics (NASDAQ:KROS) had its price target reduced by Scotiabank from $44.00 to $41.00 in a report published on Thursday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock.

Other research analysts have also recently issued research reports about the stock. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. HC Wainwright reduced their price objective on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $70.22.

Keros Therapeutics Stock Up 1.0 %

KROS opened at $10.52 on Thursday. The company has a fifty day simple moving average of $38.65 and a 200 day simple moving average of $47.61. The stock has a market cap of $426.17 million, a P/E ratio of -2.02 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the company posted ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, equities research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KROS. FMR LLC boosted its position in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Alkeon Capital Management LLC lifted its stake in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. lifted its stake in shares of Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after buying an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Finally, Holocene Advisors LP grew its stake in Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after buying an additional 154,784 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.